Exact Sciences (EXAS) announced it has entered into an agreement to acquire exclusive rights in the United States to current and future versions of Freenome’s blood-based, single indication, colorectal cancer screening tests. Under the terms of the agreement, Freenome will receive $75M in cash payable by November 2025. Additional potential payments of up to $700M are based on the achievement of certain milestones for Freenome’s blood-based CRC screening tests.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences reports Q2 EPS (1c), consensus (15c)
- Exact Sciences’ Growth Potential Bolstered by Cologuard Plus and Strategic Medicare Advantage Agreement
- EXAS Upcoming Earnings Report: What to Expect?
- Exact Sciences expands colorectal cancer screening partnership with Humana
- Buy Rating for Exact Sciences Driven by Promising CRC Screening Test and Favorable Market Outlook